Association between use of β-blockers and prostate cancer-specific survival: A cohort study of 3561 prostate cancer patients with high-risk or metastatic disease

European Urology

Volumn 65, Issue 3, 2014, Pages 635-641

  Grytli, Helene Hartvedt ^a   Fagerland, Morten Wang ^a   Fosså, Sophie D ^a,b   Taskén, Kristin Austlid ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Adrenergic receptor antagonist; Blocker; ASA; Epidemiology; High risk prostate cancer; Metastasis; Norway; Prostate cancer; Prostate cancer specific mortality; Statin

Indexed keywords

ASA; EPIDEMIOLOGY; HIGH-RISK PROSTATE CANCER; METASTASIS; NORWAY; PROSTATE CANCER; PROSTATE CANCER-SPECIFIC MORTALITY; STATIN; Β-ADRENERGIC RECEPTOR ANTAGONIST; Β-BLOCKER;

ADRENERGIC BETA-ANTAGONISTS; AGED; ASPIRIN; COHORT STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SURVIVAL RATE;

EID: 84895064442     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.01.007     Document Type: Article

References (27)

1. M. Lens Do beta-blockers slow down melanoma progression? Arch Intern Med 171 2011 1686 1687
2. D.G. Powe, and F. Entschladen Targeted therapies: using beta-blockers to inhibit breast cancer progression Nat Rev Clin Oncol 8 2011 511 512
3. E.V. Yang Role for catecholamines in tumor progression: possible use for beta-blockers in the treatment of cancer Cancer Biol Ther 10 2010 30 32
4. J.P. Campbell, M.R. Karolak, and Y. Ma et al. Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice PLoS Biol 10 2012 e1001363
5. E.K. Sloan, S.J. Priceman, and B.F. Cox et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer Cancer Res 70 2010 7042 7052
6. D. Palm, K. Lang, and B. Niggemann et al. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers Int J Cancer 118 2006 2744 2749 (Pubitemid 43673352)
7. P.H. Thaker, L.Y. Han, and A.A. Kamat et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma Nat Med 12 2006 939 944 (Pubitemid 44175146)
8. T.I. Barron, R.M. Connolly, L. Sharp, K. Bennett, and K. Visvanathan Beta blockers and breast cancer mortality: a population- based study J Clin Oncol 29 2011 2635 2644
9. A. Melhem-Bertrandt, M. Chavez-Macgregor, and X. Lei et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer J Clin Oncol 29 2011 2645 2652
10. D.G. Powe, M.J. Voss, and K.S. Zanker et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival Oncotarget 1 2010 628 638
11. V. De Giorgi, M. Grazzini, and S. Gandini et al. Treatment with beta-blockers and reduced disease progression in patients with thick melanoma Arch Intern Med 171 2011 779 781
12. S. Lemeshow, H.T. Sorensen, and G. Phillips et al. Beta-blockers and survival among Danish patients with malignant melanoma: a population-based cohort study Cancer Epidemiol Biomarkers Prev 20 2011 2273 2279
13. E.S. Diaz, B.Y. Karlan, and A.J. Li Impact of beta blockers on epithelial ovarian cancer survival Gynecol Oncol 127 2012 375 378
14. H.H. Grytli, M.W. Fagerland, S.D. Fosså, K.A. Tasken, and L.L. Haheim Use of beta-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy Prostate 73 2013 250 260
15. K.S. Choe, J.E. Cowan, J.M. Chan, P.R. Carroll, A.V. D'Amico, and S.L. Liauw Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy J Clin Oncol 30 2012 3540 3544
16. R. Gutt, N. Tonlaar, R. Kunnavakkam, T. Karrison, R.R. Weichselbaum, and S.L. Liauw Statin use and risk of prostate cancer recurrence in men treated with radiation therapy J Clin Oncol 28 2010 2653 2659
17. S.W. Marcella, A. David, P.A. Ohman-Strickland, J. Carson, and G.G. Rhoads Statin use and fatal prostate cancer: a matched case-control study Cancer 118 2012 4046 4052
18. Norwegian Prescription Database. Norwegian Institute of Public Health Web site. http://www.fhi.no/eway/default.aspx?pid=238&trg=MainArea- 5811&MainArea-5811=5903.
19. A. Heidenreich, J. Bellmunt, and M. Bolla et al. EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and treatment of clinically localised disease Eur Urol 59 2011 61 71
20. J. Fine, and R. Gray A proportional hazards model for the subdistribution of a competing risk J Am Statist Assoc 94 1999 496 509
21. M. Benish, I. Bartal, and Y. Goldfarb et al. Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis Ann Surg Oncol 15 2008 2042 2052
22. S.W. Cole, and A.K. Sood Molecular pathways: beta-adrenergic signaling pathways in cancer Clin Cancer Res 18 2012 1201 1206
23. M.J. Reiter Cardiovascular drug class specificity: beta-blockers Prog Cardiovasc Dis 47 2004 11 33 (Pubitemid 39420270)
24. E.A. Kasbohm, R. Guo, and C.W. Yowell et al. Androgen receptor activation by G(s) signaling in prostate cancer cells J Biol Chem 280 2005 11583 11589 (Pubitemid 40418471)
25. A. Yokomizo, M. Shiota, and E. Kashiwagi et al. Statins reduce the androgen sensitivity and cell proliferation by decreasing the androgen receptor protein in prostate cancer cells Prostate 71 2011 298 304
26. S.J. Freedland, M.K. Terris, E.A. Platz, and J.C. Presti Jr. Body mass index as a predictor of prostate cancer: development versus detection on biopsy Urology 66 2005 108 113 (Pubitemid 41002197)
27. L.J. Su, L. Arab, and S.E. Steck et al. Obesity and prostate cancer aggressiveness among African and Caucasian Americans in a population-based study Cancer Epidemiol Biomarkers Prev 20 2011 844 853